Technology
Health
Pharmaceutical

G1 Therapeutics

$14.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.68 (-4.51%) Today
+$0.10 (0.69%) After Hours

Why Robinhood?

You can buy or sell GTHX and other stocks, options, ETFs, and crypto commission-free!

About

G1 Therapeutics, Inc. Common Stock, also called G1 Therapeutics, is a clinical-stage biopharmaceutical company that focuses on the discovery and development of novel therapies to address significant unmet needs in oncology. Read More The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.

Employees
84
Headquarters
Research Triangle Park, North Carolina
Founded
2008
Market Cap
561.61M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
335.15K
High Today
$15.34
Low Today
$14.39
Open Price
$15.01
Volume
276.83K
52 Week High
$69.57
52 Week Low
$14.39

Collections

Technology
Health
Pharmaceutical
Therapy
Cancer Prevention
Medical
2017 IPO
US

News

Simply Wall StMar 14

The G1 Therapeutics (NASDAQ:GTHX) Share Price Is Down 57% So Some Shareholders Are Wishing They Sold

Even the best stock pickers will make plenty of bad investments. And unfortunately for G1 Therapeutics, Inc. (NASDAQ:GTHX) shareholders, the stock is a lot lower today than it was a year ago. The share price is down a hefty 57% in that time. We wouldn’t rush to judgement on G1 Therapeutics because we don’t have a long term history to look at. The falls have accelerated recently, with the share price down 46% in the last three months. This could be related to the recent financial results – you can catch up o...

117
FortuneMar 12

Trump Administration Makes Surprising Choice for FDA Interim Chief: a Career Scientist

Norman “Ned” Sharpless was named as interim head of the Food and Drug Administration Tuesday. Sharpless, the director of the National Cancer Institute, is a scientist, making the appointment a departure from the Trump administration’s pattern of appointing industry insiders and lobbyists to head federal agencies. Sharpless has served as the director of the NCI since October 2017. He also heads the aging biology and cancer section of the National Institute on Aging’s Laboratory of Genetics and Genomics. His...

62
Yahoo FinanceMar 12

Cancer Institute's Sharpless Tapped as Acting Chief of FDA

(Bloomberg) -- Ned Sharpless, the director of the National Cancer Institute, will be named temporary chief of the Food and Drug Administration, taking for now the post being vacated by Scott Gottlieb.

0

Earnings

-$1.09
-$0.91
-$0.73
-$0.55
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 2, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.